Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Discover the importance of using asset allocation to balance risk and return. This strategy can enhance your investment performance.
28,655 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
As markets navigate early-2026 volatility, three dividend-focused ETFs stand out for beginners. Low fees, broad diver...
Bernstein analysts say Bitcoin’s ‘boring’ cycle persists and the store-of-value thesis remains intact despite $2.6 bi...
A 67-year-old retiree with a $1 million nest egg weighs whether a six-figure Corvette fits into a decades-long retire...
Marvell Technology is set to report fiscal Q1 results after the close, with investors weighing AI demand, margins and...
A new IPO can spark excitement, but history shows many SPACs and tech IPOs struggle in the first year. This guide bre...
The federal debt breached $39 trillion this week as lawmakers debated a constitutional fix that failed to pass. The p...
A new survey shows a growing openness among high earners to expatriate, signaling shifting expectations for the U.S. ...
As copper prices rise and mining profits surge, retirees are increasingly flocking to copper-focused ETFs and miners ...
Coinbase widens its influence in on-chain finance by becoming the official USDC deployer on Hyperliquid, a move desig...
Inflation has squeezed most Americans, but American Express remains focused on the affluent. This article examines wh...
A clear, investor-friendly look at Iridex's Q1 2026 performance and what it could mean for the full year. Learn the n...